πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 85 of 173

  1. US 9487551

    Small molecule compounds that control mammal-pathogenic nematodes

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9487522

    SSH-2 (slingshot-2) inhibitors and methods for making and using them

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9486509

    Compositions and methods for preparing a subject for organ or non-organ implantation

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9486456

    Treatment of esophageal motility disorder using sepiapterin, tetrahydrobiopterin and derivatives thereof

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9486424

    Creatine oral supplementation using creatine hydrochloride salt

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9486423

    Redox-directed chelators targeting intracellular metal ions

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9486457

    Use of cinnabarinic acid as a modulator of immune responses in autoimmune disorders

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9486422

    Small molecule inhibitors of Mcl-1 and the uses of thereof

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9486539

    Nipah virus envelope pseudotyped lentiviruses and methods of their use

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9486474

    Interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9481692

    Heterocyclic modulators of HIF activity for treatment of disease

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9480669

    Method of destroying and preventing bacterial and fungal biofilm by amino acid infusion

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9480675

    Method for increasing muscle growth by blocking sirtuin activity

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9480725

    Fermented wheat germ proteins (FWGP) for the treatment of cancer

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9481888

    Recombinant bacterium and methods of antigen and nucleic acid delivery

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9481877

    Engineered primate L-methioninase for therapeutic purposes

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9481717

    Lectins and uses thereof

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9481662

    Seriniquinones, melanoma-specific anticancer agents

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9480785

    Nitric oxide delivery devices

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9480673

    Composition and method for treating neurodegenerative disease

    Expires Mon Oct 27 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9474784

    Therapeutic applications of SMAD7

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9474730

    Methods and compositions for use with K-ras mediated disorders

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9474830

    PEGylated fibrinogen precursor molecule

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9475832

    Phosphonates with reduced toxicity for treatment of viral infections

    Expires Mon Oct 20 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9468632

    Methods and compositions for targeting cancer stem cells

    Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9468649

    Methods of treating epilepsy with transforming growth factor beta inhibitors

    Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9470689

    N-cadherin: target for cancer diagnosis and therapy

    Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9469879

    Lymphoma prognostic methods and kits

    Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9469878

    Methods of treating cancer comprising targeting NQO1

    Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9468669

    Methods to treat dysregulated blood glucose disorders

    Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9463177

    Compounds and methods for modulating vascular injury

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9464130

    Nucleic acids encoding a cold- and menthol-sensitive receptor

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9463254

    Molecular design toward dual-modality probes for radioisotope-based imaging (PET or SPECT) and MRI

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9463216

    Poly-glutamic acid anti-anthrax compositions and methods for using the same

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9463232

    Vault compositions for immunization

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9463195

    Dissolution of amyloid fibrils by flavonoids and other compounds

    Expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9458517

    Adeno-associated virus virions with variant capsid and methods of use thereof

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9457070

    Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9456997

    Selective inhibition of Ξ²1-adrenergic receptors for the treatment of pediatric heart failure

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9458095

    Oligo-benzamide compounds and their use in treating cancers

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9457002

    Antimicrobial compositions comprising glyceryl nitrates

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9457103

    Adeno-associated virus virions with variant capsid and methods of use thereof

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9457006

    Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9457030

    Compositions and methods for the treatment of juvenile neuronal ceroid lipofuscinosis and related disorders

    Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9452215

    Bourvadin derivatives and therapeutic uses thereof

    Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9453068

    Antibodies that neutralize botulinum neurotoxins

    Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9452182

    Collateral gene inactivation biomarkers and targets for cancer therapy

    Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9452175

    Pregnancy hormone combination for treatment of autoimmune diseases

    Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.